Stockscreener 앱 받기
33.05
4.65%
1.47
시장 영업 전:
33.70
0.65
+1.97%
전일 마감가:
$31.58
열려 있는:
$32.14
하루 거래량:
3.28M
Relative Volume:
0.95
시가총액:
$2.65B
수익:
-
순이익/손실:
$-96.66M
주가수익비율:
-15.37
EPS:
-2.15
순현금흐름:
$-83.73M
1주 성능:
+21.46%
1개월 성능:
+310.05%
6개월 성능:
+714.04%
1년 성능:
+391.82%
1일 변동 폭
$31.32
$33.44
1주일 범위
$25.62
$33.50
52주 변동 폭
$2.86
$33.50
올레마 Stock (OLMA) Company Profile
명칭
Olema Pharmaceuticals Inc
전화
(415) 651-3316
주소
780 BRANNAN STREET, SAN FRANCISCO
OLMA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
33.05 | 2.53B | 0 | -96.66M | -83.73M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
올레마 Stock (OLMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-08 | 개시 | Guggenheim | Buy |
| 2025-08-12 | 재확인 | Citigroup | Buy |
| 2024-04-02 | 개시 | Goldman | Buy |
| 2024-01-30 | 개시 | Citigroup | Buy |
| 2023-07-21 | 개시 | Oppenheimer | Outperform |
| 2023-05-05 | 개시 | CapitalOne | Overweight |
| 2023-02-22 | 개시 | Credit Suisse | Outperform |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-06-09 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-02-28 | 개시 | H.C. Wainwright | Neutral |
| 2021-12-07 | 재개 | Cowen | Outperform |
| 2020-12-14 | 개시 | Canaccord Genuity | Buy |
| 2020-12-14 | 개시 | Cowen | Outperform |
| 2020-12-14 | 개시 | JP Morgan | Overweight |
| 2020-12-14 | 개시 | Jefferies | Buy |
모두보기
올레마 주식(OLMA)의 최신 뉴스
Birchview Capital LP Invests $571,000 in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Raised to $48.00 - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Raised to $60.00 - MarketBeat
OLMA Stock: Citigroup Raises Price Target to $60, Maintains Buy - GuruFocus
Olema Pharmaceuticals (OLMA): HC Wainwright & Co. Raises Price T - GuruFocus
Olema Oncology (OLMA) Price Target Raised by Citi Amid Positive Trial Data - GuruFocus
Oppenheimer Raises Price Target for Olema Pharmaceuticals (OLMA) to $48 | OLMA Stock News - GuruFocus
OLMA: Goldman Sachs Raises Price Target to $38 on Maintained Buy Rating | OLMA Stock News - GuruFocus
The Goldman Sachs Group Issues Positive Forecast for Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Up 6% Following Analyst Upgrade - MarketBeat
Olema (OLMA) Hits 4-Year High as Jefferies Hikes PT - Finviz
HC Wainwright Raises Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $45.00 - MarketBeat
Olema Pharmaceuticals stock price target raised to $45 at H.C. Wainwright - Investing.com Canada
HighVista Strategies LLC Acquires 66,245 Shares of Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Jefferies raises Olema Pharmaceuticals stock price target to $43 on SERD validation - Investing.com UK
Olema Pharmaceuticals (OLMA) Stock Hits New 52‑Week High on December 10, 2025: What Investors Need to Know - ts2.tech
Olema Pharmaceuticals (NASDAQ:OLMA) Hits New 1-Year HighHere's Why - MarketBeat
Olema Oncology (OLMA) Shares Surge Over 11% - GuruFocus
Olema Pharmaceuticals stock hits 52-week high at $29.57 By Investing.com - Investing.com Canada
Roche's SERD Trial Boosts Olema Pharmaceuticals (OLMA) Stock - GuruFocus
Olema Pharmaceuticals stock hits 52-week high at $29.57 - Investing.com
Diadema Partners LP Increases Stock Holdings in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Sets New Standards In Oncology - Kalkine Media
Olema Pharmaceuticals joins SABCS25 to advance breast cancer therapies - Traders Union
Olema Pharmaceuticals (NASDAQ:OLMA) Trading Down 7.7%Here's Why - MarketBeat
Olema Pharmaceuticals (OLMA) Stock: Latest News, Forecast & Analysis as of December 9, 2025 - ts2.tech
Olema Pharmaceuticals (NASDAQ:OLMA) Moves Forward with Clinical Trials - Kalkine Media
XTX Topco Ltd Makes New Investment in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals, Inc. $OLMA Shares Bought by Schroder Investment Management Group - MarketBeat
Affinity Asset Advisors LLC Lowers Holdings in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals (OLMA) price target increased by 53.92% to 37.23 - MSN
Olema Pharmaceuticals Inc Stock Analysis and ForecastVolume Profile Analysis & Turn Data into Profits With Our Strategies - earlytimes.in
Why Olema Pharmaceuticals Inc. stock is rated strong buyChart Signals & Capital Protection Trade Alerts - Newser
Why retail investors favor Olema Pharmaceuticals Inc. stockMarket Sentiment Review & Long-Term Growth Plans - Newser
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Olema Pharmaceuticals seeks senior medical director to advance oncology care - Traders Union
Olema Pharmaceuticals (OLMA) Stock Analysis Report | Financials & Insights - Benzinga
H.C. Wainwright Backs Olema Pharmaceuticals (OLMA) as Phase 3 Trials Advance - MSN
Olema Pharmaceuticals (OLMA): Assessing Valuation Following $190 Million Equity Offering and Underwriter Changes - Sahm
Olema Pharmaceuticals (NASDAQ:OLMA) Reaches New 1-Year HighHere's What Happened - MarketBeat
Will Olema Pharmaceuticals Inc. stock pay special dividends2025 Price Targets & Weekly Watchlist for Hot Stocks - BỘ NỘI VỤ
Olema Pharmaceuticals stock hits 52-week high at 27.25 USD By Investing.com - Investing.com Canada
Olema Pharmaceuticals stock hits 52-week high at 27.25 USD - Investing.com
15,000 Shares in Olema Pharmaceuticals, Inc. $OLMA Bought by Titleist Asset Management LLC - MarketBeat
Olema Pharmaceuticals : Statement of Changes in Beneficial Ownership (Form 4) - marketscreener.com
Dir Rappaport Acquires 35,868 Of Olema Pharmaceuticals Inc [OLMA] - TradingView
[Form 4] Olema Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Olema Pharmaceuticals Reports Increased Losses Amid R&D Expansion - MSN
Olema Pharmaceuticals (OLMA): Evaluating the Current Valuation After a Strong Run-Up in Recent Months - Yahoo Finance
Goldman Sachs Raises Stake in Olema Pharmaceuticals, Inc. (OLMA) - MSN
LifeSci Capital Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA) - The Globe and Mail
올레마 (OLMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):